Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
41.85
-0.06 (-0.14%)
At close: Nov 4, 2026, 4:00 PM EST
41.70
-0.15 (-0.36%)
After-hours: Nov 4, 2026, 7:57 PM EST
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Teva Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $48.94. The average 1-year stock price forecast is 16.94% higher than the current stock price, while the lowest is $42 (+0.36%) and the highest is $57 (+36.20%).
Price Target: $48.94 (+16.94%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Teva Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|
| Strong Buy | 4 | 8 | 9 |
| Buy | 3 | 4 | 4 |
| Hold | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 8 | 13 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $52 → $54 | Buy | Reiterates | $52 → $54 | +29.03% | Nov 4, 2026 |
| Scotiabank | Scotiabank | Buy Maintains $47 | Buy | Maintains | $47 | +12.31% | Nov 4, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $44 | Buy | Reiterates | $44 | +5.14% | Oct 23, 2026 |
| Barclays | Barclays | Buy Maintains $47 | Buy | Maintains | $47 | +12.31% | Oct 16, 2026 |
| Leader Capital Markets | Leader Capital Markets | Buy Maintains $49 | Buy | Maintains | $49 | +16.30% | Oct 13, 2026 |
Financial Forecast
Revenue This Year
16.76B
from 17.26B
Decreased by -2.89%
Revenue Next Year
17.31B
from 16.76B
Increased by 3.29%
EPS This Year
2.06
EPS Next Year
3.11
from 2.06
Increased by 50.90%
EPS and Forward PE are based on non-GAAP adjusted numbers.